Open access · CC-BY
via OpenAlex
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
Luís M. A. Oliveira, Thomas Gasser, Robert H. Edwards, Markus Zweckstetter, Ronald Melki, Leonidas Stefanis, Hilal Ahmed Lashuel, David L. Sulzer, Kostas Vekrellis, Glenda Margaret Halliday, Julianna J. Tomlinson, Michael G. Schlossmacher, Poul Henning Jensen, Julia Maria Schulze-Hentrich, Olaf Rieß
npj Parkinson s Disease · 2021 · ▲ 168 citations
Abstract
With the advent of the genetic era in Parkinson's disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein's varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41531-021-00203-9
- Canonical
- link ↗
- Fetched
- 2026-10-21 MST
Cite this
APA
Oliveira, L.M.A., Gasser, T., Edwards, R.H., Zweckstetter, M., Melki, R., Stefanis, L., Lashuel, H.A., Sulzer, D.L., Vekrellis, K., Halliday, G.M., Tomlinson, J.J., Schlossmacher, M.G., Jensen, P.H., Schulze-Hentrich, J.M., Rieß, O., Hirst, W.D., El‐Agnaf, O.M.A., Mollenhauer, B., Lansbury, P.T., & Outeiro, T.F. (2021). Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease. <em>npj Parkinson s Disease</em>. https://doi.org/10.1038/s41531-021-00203-9
Vancouver
Oliveira LMA, Gasser T, Edwards RH, Zweckstetter M, Melki R, Stefanis L, et al. Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease. npj Parkinson s Disease. 2021. doi:10.1038/s41531-021-00203-9.
BibTeX
@article{lus2021Alphas,
title = {Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease},
author = {Luís M. A. Oliveira and Thomas Gasser and Robert H. Edwards and Markus Zweckstetter and Ronald Melki and Leonidas Stefanis and Hilal Ahmed Lashuel and David L. Sulzer and Kostas Vekrellis and Glenda Margaret Halliday and Julianna J. Tomlinson and Michael G. Schlossmacher and Poul Henning Jensen and Julia Maria Schulze-Hentrich and Olaf Rieß and Warren D. Hirst and Omar M. A. El‐Agnaf and Brit Mollenhauer and Peter T. Lansbury and Tiago F. Outeiro},
journal = {npj Parkinson s Disease},
year = {2021},
doi = {10.1038/s41531-021-00203-9},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Lancet 2009
Citation only
Parkinson's disease
The Lancet 2021
Open access · OA
Parkinson's disease
Handbook of clinical neurology 2022
Preprint · OA
T cells, α-synuclein and Parkinson disease
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2011
Open access · OA
α-Synuclein misfolding and Parkinson's disease
Frontiers in Neuroscience 2025
Open access · CC-BY
Gut dysbiosis as a potential driver of Parkinson’s and Alzheimer’s disease pathogenesis
Neurobiology of Disease 2012
Preprint · CC-BY